Phase 1
N=25
Effects of Commonly Used Medications on Mood and Choice
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT03652740 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Placebo (Drug); Methylphenidate (Drug); Nicotine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins University
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participant Subjective Ratings of Drug Liking (Peak Change) |
1.00; -0.11; 0.88; 0.33; 1.63; -0.50 | — |
| SECONDARY Participant Subjective Ratings of Drug Value |
0.19; 0.06; 0.41; -1.97; 0.06; -1.14 | — |
Summary
This non-treatment study will examine how commonly used prescription or over-the-counter medications may influence mood and medication preference.
Eligibility Criteria
Inclusion Criteria
- Age 18-65
- Fluent in written and spoken English and is capable of understanding and complying with the protocol
- Medically healthy
- Non-smoker
- Appropriate dietary/over-the-counter/prescription/illicit drug use history
- Body Mass Index between 18.5 and 35
- Appropriate use of birth control in females e.g., barrier methods, hormonal contraceptives, Intra Uterine Devices (IUDs)
Exclusion Criteria
- Known hypersensitivity to administered drugs
- Current neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary or metabolic disease for which administration of the study drugs would be contraindicated
- Current psychiatric or substance use condition that would interfere with study participation
- Diastolic blood pressure >90 mmHg or a systolic pressure of >140 mmHg
- Use of medications that would interfere with study participation
- Past prescriptions that may affect study participation
- Unwilling or unable to comply with the protocol
- Any other serious disease or condition that might affect life expectancy or make it difficult to successfully manage the subjects according to the protocol
- Females: Pregnancy, breastfeeding, or plans to become pregnant
Data sourced from ClinicalTrials.gov (NCT03652740). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.